Krystal Biotech, Inc. — Director's Dealing 2025

Jul 11, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Krystal Biotech, Inc. (KRYS)
CIK: 0001711279
Period of Report: 2025-07-09

Reporting Person: Krishnan Suma (Director, President, R&D, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-07-09	Common Stock	S	200	$150.139	Disposed	1463511	Direct
2025-07-10	Common Stock	S	6500	$150.2252	Disposed	1457011	Direct
2025-07-10	Common Stock	S	300	$151.3867	Disposed	1456711	Direct
2025-07-09	Common Stock	S	200	$150.07	Disposed	1532856	Indirect
2025-07-10	Common Stock	S	6627	$150.2184	Disposed	1526229	Indirect
2025-07-10	Common Stock	S	300	$151.3867	Disposed	1525929	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	90000	Indirect
Common Stock	50000	Indirect

Footnotes

F1: The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person that started on September 12, 2024 and will terminate on September 13, 2025 .

F2: The transaction was executed in multiple trades ranging from $150.1200 to $150.1600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F3: The transaction was executed in multiple trades ranging from $150.0000 to $150.8500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F4: The transaction was executed in three trades of 100 shares each at $151.350, $151.40, and $151.41, respectively. The price reported above reflects the average sale price.

F5: Directly beneficially owned by the Krishnan Family Trust. The reporting person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.

F6: The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan, that started on September 12, 2024 and will terminate on September 13, 2025.

F7: The transaction was executed in two trades of 100 shares each at $150 and $150.14, respectively. The price reported above reflects the average sale price.

F8: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person.